My ePortfolio Register   

HR–positive advanced breast cancer: Ribociclib improved PFS for pre and perimenopausal women

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 07.12.17
Views: 246

Prof Debu Tripathy - MD Anderson Cancer Center, Houston, USA

Prof Tripathy speaks at a SABCS 2017 press session about data from the MONALEESA-7 phase III clinical trial.

Adding the CDK4/6 inhibitor ribociclib to standard endocrine therapy with temporary ovarian suppression significantly improved progression-free survival for pre- and perimenopausal women with advanced hormone receptor–positive (HR-positive), HER2-negative breast cancer.

Read the news story for more.

Related videos

follow us

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence